PicoCELA Inc. (NASDAQ:PCLA) Sees Significant Drop in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the target of a large drop in short interest in February. As of February 13th, there was short interest totaling 13,443 shares, a drop of 70.2% from the January 29th total of 45,053 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average trading volume of 16,314 shares, the days-to-cover ratio is currently 0.8 days. Based on an average trading volume of 16,314 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.5% of the company’s stock are short sold.

Institutional Trading of PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd purchased a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, PicoCELA has a consensus rating of “Sell”.

PicoCELA Stock Down 2.3%

PicoCELA stock traded down $0.10 during midday trading on Friday, reaching $4.28. The company’s stock had a trading volume of 7,366 shares, compared to its average volume of 60,039. The company has a current ratio of 2.13, a quick ratio of 1.57 and a debt-to-equity ratio of 0.02. The stock’s 50-day simple moving average is $6.53 and its 200-day simple moving average is $10.07. PicoCELA has a 52-week low of $3.46 and a 52-week high of $179.38.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.